BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 14583759)

  • 1. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
    Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
    Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].
    Dehesa LA; Vilar-Alejo J; Valerón-Almazán P; Carretero G
    Actas Dermosifiliogr; 2009 Sep; 100(7):571-85. PubMed ID: 19715642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
    Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
    Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
    Weide B; Eigentler TK; Pflugfelder A; Zelba H; Martens A; Pawelec G; Giovannoni L; Ruffini PA; Elia G; Neri D; Gutzmer R; Becker JC; Garbe C
    Cancer Immunol Res; 2014 Jul; 2(7):668-78. PubMed ID: 24906352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
    Powell S; Dudek AZ
    Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-lesional interleukin-2 for the treatment of in-transit melanoma.
    Boyd KU; Wehrli BM; Temple CL
    J Surg Oncol; 2011 Dec; 104(7):711-7. PubMed ID: 21744347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma.
    Oratz R; Hauschild A; Sebastian G; Schadendorf D; Castro D; Bröcker EB; Orenberg EK
    Melanoma Res; 2003 Feb; 13(1):59-66. PubMed ID: 12569286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
    Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
    Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients.
    Ridolfi L; Ridolfi R; Ascari-Raccagni A; Fabbri M; Casadei S; Gatti A; Trevisan G; Righini MG
    J Eur Acad Dermatol Venereol; 2001 May; 15(3):218-23. PubMed ID: 11683284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
    Ridolfi L; Ridolfi R
    Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma.
    Weide B; Derhovanessian E; Pflugfelder A; Eigentler TK; Radny P; Zelba H; Pföhler C; Pawelec G; Garbe C
    Cancer; 2010 Sep; 116(17):4139-46. PubMed ID: 20564107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High-dose Roncoleukin in patients with disseminated cutaneous melanoma: a phase 1 study].
    Moiseenko VM; Novik AV; Orlova RV; Protsenko SA; Mikhaĭlichenko TD; Semenova AI; Tiukavina NV
    Vopr Onkol; 2005; 51(5):546-9. PubMed ID: 16756008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional therapy of metastatic spreading melanoma with beta-interferon.
    Rapprich H; Hagedorn M
    J Dtsch Dermatol Ges; 2006 Sep; 4(9):743-6. PubMed ID: 16928243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
    J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
    Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
    J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bolus high dose interleukin-2 for the treatment of malignant melanoma.
    Pappo I; Lotem M; Klein M; Orda R
    Isr Med Assoc J; 2001 Mar; 3(3):169-73. PubMed ID: 11303372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of arsenic trioxide in patients with metastatic melanoma.
    Kim KB; Bedikian AY; Camacho LH; Papadopoulos NE; McCullough C
    Cancer; 2005 Oct; 104(8):1687-92. PubMed ID: 16130126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
    Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
    Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.